A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

225

Enrollment

INDUSTRY

Sponsor class

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: talaporfin sodium
DRUG: Saline
DEVICE: Drug Activator 100 J/cm
DEVICE: Drug Activator 200 J/cm

Sponsor

Light Sciences Oncology

Collaborators

[object Object]